

## Neurodevelopmental Outcomes in the Drug-Exposed Premature Infant

### ***Internet Enduring Material***

***Release Date:*** 05/06/2022

***Expiration Date for Credit:*** 05/05/2025

***Content was originally presented as part of the Pediatrix Neonatology Grand Rounds series on May 4, 2022.***

### ***Accreditation***

The Pediatrix Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Pediatrix Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 1 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Pediatrix Center for Research, Education, Quality and Safety is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

The Pediatrix Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 1 *nursing contact hour*. Participants should claim only the claim credit commensurate with the extent of their participation in the activity.

### ***Time to Complete***

The estimated time for completion of this Internet Enduring Material is 65 minutes.

### ***Target Audience***

This presentation is intended for physicians, advanced practice providers, and other clinicians practicing within the Neonatology specialty.

### ***Mitigation of Relevant Financial Relationships***

The Pediatrix Center for Research, Education, Quality and Safety adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies within the 24 months prior to their involvement with the CE activity. All relevant financial relationships listed have been mitigated prior to the commencement of the activity. Beyond the disclosure of financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

### ***Disclosure of Relevant Financial Relationships***

**David M. Riley, MD, MBA**, faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose.

**Timothy Biela, MD, Nicole Brenson, Vicki Leamy, DNP, NNP-BC**, planners of this educational activity, have no relevant financial relationships with ineligible companies to disclose.

**FDA Disclosures**

Dexmedetomidine: off-label; Morphine: off-label; Midazolam: off-label; Ketorolac: off-label; Acetaminophen IV: off-label; Clonidine: off-label; Gabapentin: off-label; Fentanyl: off-label; Atropine: off-label; Rocuronium: off-label; Naloxone: labeled for opioid induced depression.

**Commercial Support**

There is no commercial support for this educational activity.

**Overview**

The purpose of this educational activity is to enhance clinician knowledge in the ever-changing area of complications associated with Neonatology as well as promising new techniques and interventions for improving outcomes in this arena. This presentation will address the known risk of developmental impairment from sedative and pain control medications used in NICU patients.

**Objectives**

*At the conclusion of this activity, the participant will be able to:*

- Discuss the available data on the long-term developmental impact of medications used in the NICU for pain control and sedation.

**ACGME/ABMS Competencies**

- Patient Care & Procedural Skills
- Medical Knowledge
- Practice-Based Learning & Improvement
- Systems-Based Practice

**IOM Competencies**

- Provide patient-centered care
- Employ evidence-based practice
- Apply quality improvement

**Participation and Credit**

Participants are expected to review all content in the video, access reference materials as needed for additional self-directed learning, take and score 75% or greater correct on the post-test, and complete the evaluation in order to earn *AMA PRA Category 1 Credit(s)*<sup>™</sup>, or nursing contact hour(s).

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of credit for this activity, please consult your professional licensing board.

**Contact**

Should you have any questions or concerns, please contact us at [continuing.education@pediatrix.com](mailto:continuing.education@pediatrix.com)